From the Journals

21-gene assay predicts survival in male and female breast cancer


 

FROM THE JOURNAL OF CLINICAL ONCOLOGY


At the other end of the scale, RS lower than 11, especially RS 0, were seen more frequently in men than in women, except among those younger than 40 years.

Looking at individual gene expression profiles, the authors found that mean gene expression was higher in men for genes associated with ER, proliferation, and invasion. ER expression was lowest and PR expression was highest in women younger than 50 years, but ER expression increased progressively with age.

Among men, those younger than 50 years had slightly lower ER and PR expression than did older men.

In the analysis of SEER survival data, they found that 5-year breast cancer severity score (BCSS) was 99% for men with RS below 18, 95.7% for those with RS between18 and 30, and 81% for those with RS of 31 or higher. Among women, 5-year BCSS was 99.5% for those with RS under 18, 98.6% for those with RS between 18 and 30, and 94.9% for those with RS of 31 or higher.

Pages

Recommended Reading

Breast cancer care delayed when patients have high deductibles
MDedge Hematology and Oncology
Age at time of breast cancer diagnosis differs by race/ethnicity
MDedge Hematology and Oncology
CECCY: Carvedilol didn’t curb cardiotoxicity in breast cancer patients
MDedge Hematology and Oncology
Gaps exist in receipt of clinically indicated genetic counseling after breast cancer diagnosis
MDedge Hematology and Oncology
Fulvestrant plus neratinib reversed treatment-acquired HER2 mutations in metastatic ER+ breast cancer
MDedge Hematology and Oncology
Accelerated breast irradiation advocated by ASTRO guideline
MDedge Hematology and Oncology
Late toxicities with PARP inhibitor plus RT in inflammatory breast cancer
MDedge Hematology and Oncology
HDAC inhibition may boost immune therapy efficacy in breast cancer
MDedge Hematology and Oncology
Over one-third report financial burden from breast cancer treatment
MDedge Hematology and Oncology
Think about breast cancer surveillance for transgender patients
MDedge Hematology and Oncology